University of Heidelberg, Dept. of Cardiology
Heidelberg, 69120, Germany
NCT Number: NCT01210157
The purpose of this study is to determine whether galectin-3 binding protein plasma levels can predict adverse cardiovascular events in patients with coronary artery disease and/or heart failure.
Looking for future studies?
Notify MeAll sexes
Observational
Heidelberg, 69120, Germany
Chronic heart failure represents an important cause of disease burden in Western countries. Heart failure can be either caused by vascular disease (i.e. cardiomypathy (CMP) due to coronary artery disease ("ischemic/ICMP")) or by myocardial conditions (i.e. dilated cardiomyopathies (DCMP) resulting from other causes like familial disposition, drug toxicity, etc.). Gold standard for the diagnosis of CMPs is the coronary angiography in conjunction with left ventricular angiography and myocardial biopsy, non-invasive markers include C-reactive protein (CRP) for ICMP and brain natriuretic protein (BNP) for DCMP. We have previously identified G3BP to be overexpressed in foam cells and plasma-derived microparticles, both potentially important in formation of atherosclerotic plaque. Galectin-3 binding protein (G3BP) is a secreted protein that is involved in cell adhesion and immune activation. The purpose of the current study is to test, whether G3BP plasma levels (a) are able to non-invasively differentiate causes of CMP and (b) are a suitable means for future risk assessment in CMP patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: up to five years
Time frame: up to five years
Time frame: up to five years
Time frame: up to five years
Time frame: up to five years
Time frame: up to five years
Time frame: up to five years
Time frame: up to five years
Time frame: up to five years
Time frame: up to five years
Time frame: up to five years
Time frame: up to five years
Time frame: up to five years
Time frame: up to five years
Time frame: up to five years
Time frame: up to five years
Time frame: up to five years
Heidelberg University
Other
GALectin-3 Binding Protein for Risk Assessment in Coronary arTery dIsease and Chronic Heart Failure
Acronym: GALACTIC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03749343
Arterial Occlusive Diseases, Arteriosclerosis
Bad Nauheim, Hesse, Germany
View Trial DetailsNCT05377320
Arterial Occlusive Diseases, Arteriosclerosis
Milwaukee, Wisconsin, United States
View Trial DetailsNCT04976348
Arrhythmias, Cardiac, Arterial Occlusive Diseases
Maastricht, Limburg, Netherlands
View Trial DetailsNCT02407197
Arterial Occlusive Diseases, Arteriosclerosis
Sydney, New South Wales, Australia
View Trial Details